Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C31H40N4O6 |
Molecular Weight | 564.6725 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC[C@@H](NC(=O)N1[C@@H](OC2=CC=C(C=C2)C(=O)N3CCN(C)CC3)C(CC)(CC)C1=O)C4=CC=C5OCOC5=C4
InChI
InChIKey=ZSDCIRYNTCVTMF-GIGWZHCTSA-N
InChI=1S/C31H40N4O6/c1-5-8-24(22-11-14-25-26(19-22)40-20-39-25)32-30(38)35-28(37)31(6-2,7-3)29(35)41-23-12-9-21(10-13-23)27(36)34-17-15-33(4)16-18-34/h9-14,19,24,29H,5-8,15-18,20H2,1-4H3,(H,32,38)/t24-,29+/m1/s1
Molecular Formula | C31H40N4O6 |
Molecular Weight | 564.6725 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/10749744Curator's Comment: description was created based on several sources, including:
http://pubs.acs.org/doi/abs/10.1021/op015507o
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10749744
Curator's Comment: description was created based on several sources, including:
http://pubs.acs.org/doi/abs/10.1021/op015507o
DMP-777 (also termed L-694458) a cell permeant b-lactam inhibitor of a human leukocyte elastase was developed for treatment cystic fibrosis, juvenile rheumatoid arthritis.
Originator
Sources: https://www.google.ch/patents/US6124107
Curator's Comment: # Merck & Co., Inc.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL248 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9767628 |
23.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10833483
DMP-777 was administered to CD-1 rats by oral gavage 200 mg/kg/day
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9767628
Perfusing tracheal submucosal gland cells with 100 nM HNE plus 400 nM DMP-777 after pretreatment with DMP-777 alone resulted in the release of significantly less MGC during the test period than in the case of perfusion with 100 nM HNE alone
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:42:47 GMT 2023
by
admin
on
Fri Dec 15 15:42:47 GMT 2023
|
Record UNII |
3Q0469283P
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
96496
Created by
admin on Fri Dec 15 15:42:47 GMT 2023 , Edited by admin on Fri Dec 15 15:42:47 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID00166251
Created by
admin on Fri Dec 15 15:42:47 GMT 2023 , Edited by admin on Fri Dec 15 15:42:47 GMT 2023
|
PRIMARY | |||
|
3Q0469283P
Created by
admin on Fri Dec 15 15:42:47 GMT 2023 , Edited by admin on Fri Dec 15 15:42:47 GMT 2023
|
PRIMARY | |||
|
C105999
Created by
admin on Fri Dec 15 15:42:47 GMT 2023 , Edited by admin on Fri Dec 15 15:42:47 GMT 2023
|
PRIMARY | |||
|
177992
Created by
admin on Fri Dec 15 15:42:47 GMT 2023 , Edited by admin on Fri Dec 15 15:42:47 GMT 2023
|
PRIMARY | |||
|
157341-41-8
Created by
admin on Fri Dec 15 15:42:47 GMT 2023 , Edited by admin on Fri Dec 15 15:42:47 GMT 2023
|
PRIMARY |